New XXXX analogs in @entity0 .

@entity1 @entity632 @entity137 @entity0 @entity4349 @entity29800 @entity8779 @entity1259 @entity1370
To test the activity and @entity137 of new @entity4349 analogs, a series of Phase II disease-oriented studies were performed in @entity1 with @entity0 previously untreated with @entity632 . All drugs were administered every 3 weeks, and the doses in mg/m2 were as follows: @entity632 and @entity1259 75 i.v., @entity29800 35 i.v., @entity8779 13 i.v. and 45 p.o. When @entity1259 was tested vs @entity632 , both response rate (13 of 21 or 62% vs 11 of 21 or 52%) and median response duration (11 months vs 13 months) were comparable. In 24 @entity1 , @entity29800 yielded complete plus partial response in 21% with a median duration of 15 months. In 27 @entity1 given @entity8779 intravenously the response rate was 11% for 4 months and the corresponding findings when the drug was administered orally to 25 @entity1 were 24% for 8 months. Acute @entity137 manifestations were lower following treatment with all three analogs compared to @entity632 . @entity1370 , as documented by echocardiography, systolic time interval and left ventricular ejection fraction was virtually absent following therapy with @entity1259 and @entity8779 . After a median cumulative dose of 600 mg/m2 for @entity632 -treated @entity1 there was a significant fall in LVEF compared to basal values. Similar findings were observed after a median cumulative dose of 210 mg/m2 for @entity29800 . We conclude that @entity1259 is as effective as @entity632 but comparatively less @entity137 when administered at the same dose schedule. At the doses and schedules utilized in this study, @entity29800 and @entity8779 resulted less active in @entity0 .
